Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

36
Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the...
36
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

1.1K
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
1.1K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

24
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features...
24
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The dynamic adrenal response of children to cardiac surgery and cardiac catheterisation.

The Journal of clinical endocrinology and metabolism·2026
Same author

MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up.

Alcohol and alcoholism (Oxford, Oxfordshire)·2025
Same author

Corrigendum: L-DOPA increases slow-wave sleep duration and selectively modulates memory persistence in older adults.

Frontiers in behavioral neuroscience·2024
Same author

[Towards a new way to classify diabetes mellitus].

Revue medicale suisse·2024
Same author

"The worst thing is lying in bed thinking 'I want a cigarette'" a qualitative exploration of smoker's and ex-smoker's perceptions of sleep during a quit attempt and the use of cognitive behavioural therapy for insomnia to aid cessation.

PloS one·2024
Same author

Advancements in Cortisol Detection: From Conventional Methods to Next-Generation Technologies for Enhanced Hormone Monitoring.

ACS sensors·2024

Related Experiment Video

Updated: May 1, 2026

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

2.0K

Subcutaneous pulsatile glucocorticoid replacement therapy.

Georgina M Russell1, Claire Durant, Alia Ataya

  • 1Henry Wellcome Laboratories for Integrative Neurosciences and Endocrinology, Dorothy Hodgkin Building, University of Bristol, Bristol, UK.

Clinical Endocrinology
|April 17, 2014
PubMed
Summary

Pulsatile cortisol delivery, unlike current therapies, mimics natural hormone rhythms. A new subcutaneous system effectively replicates physiological pulsatile cortisol secretion, improving hormone replacement therapy.

More Related Videos

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

9.1K
A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

26.6K

Related Experiment Videos

Last Updated: May 1, 2026

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

2.0K
Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

9.1K
A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

26.6K

Area of Science:

  • Endocrinology
  • Neuroscience
  • Pharmacology

Background:

  • Cortisol, a glucocorticoid hormone, exhibits complex ultradian and circadian rhythms.
  • Pulsatile cortisol release influences gene activation, signaling, and neuroendocrine/behavioral responses.
  • Current glucocorticoid replacement therapy provides constant hormone levels, not mimicking physiological pulsatility.

Purpose of the Study:

  • To validate a novel portable pulsatile continuous subcutaneous delivery system.
  • To assess the system's ability to replicate physiological cortisol rhythmicity.

Main Methods:

  • A portable pulsatile continuous subcutaneous delivery system was tested in healthy volunteers.
  • Dexamethasone and metyrapone suppression were used to control endogenous cortisol levels.
  • Plasma cortisol levels were monitored to assess the system's performance.

Main Results:

  • The pulsatile subcutaneous hydrocortisone delivery system demonstrated effective replication of physiological rhythms.
  • The system more closely mimics natural circadian and ultradian cortisol patterns compared to standard therapies.

Conclusions:

  • Pulsatile subcutaneous hydrocortisone delivery represents a significant advancement in hormone replacement therapy.
  • This novel system offers a more physiological approach to managing conditions requiring glucocorticoid replacement.